

Pigmentary disorders

10/12/20

Basics

Up. 10/12/20

Color of skin: caused by 4 factors:

1. Hb — $\begin{cases} \text{oxyHb} \rightarrow \text{red color} \\ \text{deoxyHb} \rightarrow \text{Blue} \end{cases}$
2. Melanin \rightarrow Brown
3. Carotenoids: obtained from plant diet — $\begin{cases} \text{Orange} \\ \text{Carot.} \end{cases}$

Melanocytes

- Dendritic, Pigment synthesizing cell that derived from 1 Neural Crest & rests bet. KCs at BMZ.
- Embryology: Melanoblast (at Neural Crest) $\xrightarrow{\text{different to}}$ Melanocytes \rightarrow Migrate to:
 - SKIN: Epid., dermis & H. Follicles.
 - Inner ear
 - Eye
 - Meninges

Important Numbers:

10/12/20

- development at 8 wks IV.
- Earliest signs of Melanization: 10 wks IV
- No: 2×10^4 (العدد) — $\begin{cases} \text{Face} \\ \text{Genitalia} \end{cases}$
- No ↓ by 8/11 yrs.

$\begin{matrix} \text{100,000} \\ (1:9) \end{matrix} \rightarrow \begin{cases} \text{MCs} : \text{KCs ratio} = 9:9 \text{ (1:4-1:10)} \\ \text{Each MC supplies Melanosomes to } 36 \text{ KCs} \end{cases}$

by process of Apoptosis (Apoptosis: part of 1 cell is released together with the secretory product) [Cytophagocytosis]

• MIC Exam.: by H & E stain: They appear as a clear cells at basal cell layer & deeply stained nucleus ---

(d.t. Artefacts Formed during Fixation of Specimen That's because MCs lack ———— (desmosomes & Tonofilaments)).

Do From clear spaces of KCs → They show ———— (cell-cell junctions Layer of Cytoplasm peripheral to the Halo).

Special Stains: (Imp. b's)

(1) Fontan-Masson (MCs & KCs) (فونتان-ماسون)

(2) DOPA oxidase react

(3) Immunohistochemical (Markers) ———— (S100, Mart-1, HMB 45)

NB DOPA oxidase React: (منه تفرق بين الخلايا) (التي تميز)

Most specific method


depends on presence of Dopa oxidase (Tyrosinase) enz.

inside MCs → So Dopa + skin Biopsy $\xrightarrow{\text{Tyrosinase}}$ Melanin products (Brown-Black deposits).

(منه تفرق بين الخلايا) Skin Melanocyte Populations (Imp. b's)

• Epidermal MCs

منه تفرق بين الخلايا
(Basal bet KCs)



• Hair-follicle MCs

Melanotic MCs
(DOPA +ve)

↓
• Interspersed bet. Nutritional cells of HF bulb.. Immediately Capping The dermal papillae (منه تفرق بين الخلايا)

منه تفرق بين الخلايا: طمارة لشعر باللون بني
Anagen

Amelanotic MC
(DOPA -ve)

• Reservoir MCs at ORS of HFs.
• Under NL skin Condrium → inactive
• Under stress (inj. UV, UVA) → Prolif. & migrate to epidermal surface → Perifollicular pigmentat (Seen on Vitiligo Treated by UVB)

Q1. what the difference bet. Melanotic & Amelanotic MCs of HFs?

Q2. difference bet. ———— (epid. MCs & Melanotic MCs of HF) ———— (منه تفرق بين الخلايا) (لا تفرق بين الخلايا) (Anagen)

NB Racial Differences in skin color is not caused by differences of MCs Number (both dark & light skinned show KC:MCs = 9:1) But this difference is due to

- (1). Melanosome difference in - ^{No} size & ^{dist} distribution
- (2). Type of Melanin - ^{Eumelanin} (Brown-black) & ^{pheomelanin} (Red/white)

In Light skin

Melanosomes \leftarrow ^{fewer} smaller packaged by memb bound complexes

In dark skin people

Melanosomes \leftarrow ^{Much} larger ^{singly dispersed}

Function of Melanocytes

(1) Melanin products

Color of skin

has umbrella like acts over KCs Nucleus \rightarrow protect them from UVL & so skin cancer (so lighter skin people ^{أكثر عرضة لظلمات الجلد})

Antioxidant \rightarrow \downarrow UVL effect on skin.

(2) MCs: secrete cytokines & express cell surface Ag \rightarrow suggest their active role in inflammation.

Disadvantage of Melanin

① ^{البيغمان} ^{مكتبة} ^آ ^{خضرة} ^{شمس} ^{عزلة} ^{ينسج}
 ٢. ^{أولئك} ^{من} ^{خارج} ^{البشرة} ^{في} ^{تزداد}
 درجة ^{عزلة} ^{الجسم}


② ^{مضيق} ^{تكوين} ^{VitD} ^{في} ^{شبه} ^{كثرة}
 مرض ^{الأسع} ^{منتشرة} ^{في} ^{الأطفال} ^{بسم} ^{الثر}

Melanocytes in Different Colors

Light Skin	Dark Skin
Stage II melanoma	Stage III & IV
Size < 0.5 cm	> 0.5 cm
No/MC < 20	> 200
Distribution: groups	disperse (single)
Degradation: Fast	slow


Pathway of epidermal melanin pigmentation

(10 Steps)



Phenylalanine aa

Melanin Synthesis



Eumelanin

- Ellipsoid melanosomes
- dark (brown-black)

Phaeomelanin

- Spherical
- Contains Cysteine
- light (Yellow or red)

للذكورة فقط (LSCC)

Types of SKIN Color = NL Pigmentation

1. Constitutive : Genetically determined
2. Facultative (Inducible) $\left\{ \begin{array}{l} \text{UVR} \\ \text{Hormones} \end{array} \right.$

Caucasoids \rightarrow White

Mongoloid \rightarrow Oriental شرقى

Negroid \rightarrow Black

Australoid \rightarrow Aboriginal

Control & Regulation of SKIN Pigmentation

- (1) Genetic factors (Constitutive)
- (2) UVR : \uparrow MCs, \uparrow Melanin synthesis, \uparrow Tyr. enz activity
- (3) Immediate Pigment darkening (IPD) & delayed Tanning (see light & SKIN).
- (4) Endocrinal : α -MSH, ACTH, Estrogen.
- (5) Biochemical Factors : IL-1 α & β , IL-6 & TGF β

Enzymes & proteins involved in Melanogenesis.

- Tyrosinase enz.
- Tyrosinase Related protein (TRP1 & 2)
- Melanocortin Receptors (MCR1)
- MIFT = Microphthalmia associated Transcription Factor

(if Mutated) \rightarrow (Waardenburg & Tietz Synd.)

Stages of Melanosome Development (4)

- | | |
|---|---|
| <ul style="list-style-type: none">• <u>Stage I</u> \rightarrow Spherical No Melanin• <u>Stage II</u> \rightarrow oval, great activity of Tyrosinase. | <ul style="list-style-type: none">• <u>Stage III</u> : as Stage II + moderate deposits of Melanin.• <u>Stage IV</u> : oval, little activity of Tyr., Much Melanin. |
|---|---|

Basics Melanocytes

خارجة
لل

NL skin color Caused by 4 Agents:-

1. Red → oxy Hb
2. Blue → deoxygenated Hb
3. Yellow-orange → exogenous from diet (Carotenoids) ← plant orange carrot
4. Brown → Melanin



Melanocytes

[def] dendritic, Pigment-synthesizing cells that derived from the Neural crest.

[Site] May be found in:

MCS

mass 1.5 gm, 15-20%

Epid. MCS No 2×10^9 cells

face genital

MCS ↓ by age (8% 110%)

development 8 wks IU
Melanizate: 10 wks IU

MCS 2 types: secretory: KC (cytokine)
Non secretory: KC (cytokine)

skin → Epid, dermis & hair follicle → ORS Bulb

- Inner ear
- Eye
- Leptomeninges
- around BVs
- around peripheral Nsk
- Coelomic Cavity

[origin]


They arise from Melano blasts w differentiate to Melanocytes either before or after Migratⁿ from Neural Crest.

Migratⁿ starts at 2.5 wks → reach epid at 8 wks
→ earliest signs of Melanizate at 10 wks.

Redistrib. Melanocytes from perinuclear zone to dendrites again (Melanophores).

[Mic] H&E

small clear, deeply stained Nuc



→ appear as a "clear cell" in basal cell layer
(with) dark staining Nucleus
the apparent halo is def artefact formed during fixatⁿ of specimen this is because
xx Melanocytes Lack [desmosomes & Tonofilaments]
DD from clear spaces of KC: they show Cell-Cell Layer of cy Perforant

Special Stain:-

(نظري)

- DOPA oxidase React (نظري)
- Silver stain (نظري) (5-100)
- Immunohistochemical (HM-45 Mart-1) → Silver stain

2

HL

EIM: ① No desmosomes or Tonofilaments


② Nucleus: Rounded or oval & double memb., the outer is rough & separated from the inner by clear zone.

③ Nucleolus: Worm-like made up of clots of small dense particles & a limiting memb.

④ Cytoplasm: Contains:
 - Mitochondria (Num.)
 - Microtubules
 - Abundant SER & YER
 - Golgi

⑤ Several mobile dendritic processes extend from each Melanocyte bet epid. cells


Melanocyte Population



- ① - at basal cell layer, just above the BM
- ② - Ratio of MCs: basal Kcs (1:4 - 1:10) (1:10 also u)
- ③ - each single MC supply 36 Kcs. Give it
- ④ - Melanosomes by process of Apocoptation = Apicop part of the cells is released together & the secretory products.

- at hair bulb immediately capping the dermal papillae (2F)
- at outer Root Sheath ORS act as a Reservoir
- ① - supplying melanin to growing epith. cells of hair shaft
 - ② - Giving hair its color

outer Root sheath MCs



• The Amelanotic MCs: proliferate & migrate upward & start actively synthesizing melanin at the infundibulum → migrate to epidermal surface when (work, stress) → skin exposed in injury or stimulated by UVL

NB • The outer Root sheath MCs represent Reservoir MC which are stimulated by PUVA to Repigment Vitiliginous Patches → perifollicular Pigment

◉ Distribution:-

• in NL Sunprotected skin: MC: KC = (1:4 or 1:10)

→ Face, Shins, Genitalia → higher No of MCs



→ in heavily, sun-damaged, facial skin: KC: MC = 1:1

• Racial differences in skin colour ^{not} caused by differences of MCs No but d.t.

No
Size
distribut
Type.

1. No, size & distribut of Melanosomes.

2. Pigment gets in KCs.

new! ◉ Pale skin → Few melanosomes that are smaller & packaged in memb-bound complexes.


المر ◉ dark skin → Much melanosomes that are large & singly dispersed.

Function of Melanocytes

- ① Melanin synth → skin color → protectn of lower skin layer from UVL
- ② Melanin: act as scavenger for metal ions & free radicals (from cell metabolism or UVR exp.)
- ③ MC → secrete cytokines & express cell surface Ag which suggest their active role in inflammatory react

كتابنا نفس
MC

Epid. Hyperpigmentation (Melanoc)



• Lentigenes

- Peutz-Jegher synd.
- PUVA
- Melanocytic Nevi
- MM

Endocrine

- Cushing
- Addison
- Acromegaly
- Hyperthyroidism
- Pheochromocytoma
- pregnancy
- OCPs
- ACTH ↑↑

Systemic Causes

- RF
- LCF
- Hemochromatosis
- Amyloidosis
- Infect
- AIDS
- Neoplastic
- Neurological
- Nutritional

3N

- Anemia
- Pellagra
- Vit A def.
- malabsorption

Drugs

Phytophot
Berloque

- EDP
- Civatte polka
- Erythrose
- Peribuccale pigmentaire

Epidermal Melanocytic Hyperpigment

Lentigo (Lentiginosus)

def: Small, pigmented, Flat or slightly raised spot with well defined edge. has brown - dark brown or black color.

Site < skin < sun exposed (Genitals) < sun protected

Histologically: ↑ Mcs No & activity

عشان تعرفوا (مبنى)

Freckles are:-

sun exposed No Melanitic
sun protected mm Lighter lentiginosus

Types of Lentigo

① Lentigo simplex:-

- Commonest
- at birth or Early childhood.
- XX. (not) ass. with sun exposure or any medical conditions.

Site: Skin, oral, Genital, Nail

② Solar Lentigo: (Brown or Liver Spots)

- at sun exposed, (not) ass. with diseases.
- DD: Freckles (improved by sun but not lentigo)

③ Ink Spot Lentigo:

Black one among solar ones.

④ PUVA Lentigo: d.t. PUVA (H)

⑤ Radiation N: d.t. Radiation

⑥ Tanning bed Lentigo.

⑦ oral & Labial - vulval & penile Lentigo.

⑧ Generalized = Eruptive = Lentiginosis profusa

⑨ A gminated Lentiginosis / Zosteriform / Partial unilat. (PUL)

- Segmental, stop at middle line
- ± assoc. diseases

⑩ Inherited : AD ✓

⑪ Syndrome Associated :

"ay"

(HL)

① Xeroderma pigmentosum (XP)

② LEOPARD Synd

① = lentigenes

② = Electrocardiac Conduction defect.

③ = Ocular Hypertelorism = ↑ distance bet. the 2 corners of pupils of eye.

④ = Pulmonary stenosis

⑤ = Abnormalities of Genitalia

⑥ = Retarded growth

⑦ = Deafness

③ Peutz-Jeghers Synd ✓

① Lentigenes

①. perioral → mouth

② oral : persistent oral leucism

oral & perioral
Eye & Nose.

Hands, feet, fingers, Toes
and genital.

② Intest. Polyps (B9 Hamartomas)

• Small intestine (sp. Jejunum) ay

• Risk of intussusception & (Mg)

• Abd. Pain & bleeding

• Other Types of Mg ±

(5%)
"CPS"

• lentigenes any where but Commonest
at lower lip + dorsum of Hand

• Polyposis any where in GIT (but)

→ Commonest
at: Jejunum

AD
Mutation in Serine
threonine kinase
chr. 19 p13.3

Rarely → polyps absent

INVS : Barium &
endoscopy
12 Ys

©, ©

2 other Synds

در سوء

Related to PJS

Harmless Synd

Laguer Hunziker Synd.

- 1- Lentigines:
lower lip.
sp. at < Buccal cavity
others: Tongue, fingers, Genitals.

Pigm. may be macular (or) diffuse (as Addison)

2. Pigmented Nail
streaks (or even half or Total Nail)

3. No. intestinal Polyps

Cronkhite Canada Synd.

pigm 1- Lentigines at: fingers,

diffuse macular extremities (no mm)
Volar dorsal fingers Hand Limbs.
+ diffuse pigm. of velar fingers.

2. Intestinal Polyps (?? Mg)

3. Hair loss (Adenoma-tous) → 10%

4. Nail changes:
thinning, splitting & Separation.
5. diarrhoea

⊕ protein losing Enteropathy
→ Malabs → Hyper pigm.
HMB Malabs. HMB → ↓ pigm.

HL

N.B.

Myxoma =

Tm of primitive CT

→ Tm of CT =

Mexoid (Mucoid) back.

Ground → Commonest site is Heart.

MYXOMA Syndromes = Carney Complex

(Syndromes = Atrial Myxomas + Lentigines)

They are 3

1. LAMB

Lentigines: Lip, face, sclera.

Atrial Myxomas.

MucoCut " : Breast, Shoulder
Tongue.

Blue Nevi.

2. NAME Syndrome

- Nevi
- Atrial Myxoma
- Myxoid NF
- Ephelides

NB Carney complex / synd: { LAMB: Lentigines
NAME: Freckles

(i) AD
Melano Cortin - 1 R
Gene Mutated

(ii) Common in Fair skin
red / Blond
Hair Individ.

Ephelides = Freckles = Ephelis

Well defined brown Hyperpig.
macules ≤ 0.5 cm in diameter
usually at sun exposed areas

AET

Isolated finding

Not ass. \bar{e} any
systemic disorders.

ass. \bar{e} other
disorders

① NAME synd :

N = Nevi
A = atrial myxoma
M = myxoid
Neurofibromatosis
E = Ephelides.

Crow's
Sign.

② Axillary Freckling
(NF1) ✓

③ Freckle "like" pigm.
Seen in XP, Moynahan's syn
& Drageria.

Melasma* (Greek melas = black)

It is a relatively common acquired, symmetric hypermelanosis characterized by irregular light to gray-brown macules (Fig. 9-11), see also Regional Dermatology, Vol I, Fig. 61.

Sites: There is a predilection for sun-exposed areas, mainly the cheeks (malar prominences), forehead, upper lip, nose and chin.

It is most commonly observed in women in child-bearing age with dark complexion (skin types IV and V) but it has been reported in males in 10% of cases.

Clinical patterns

1. Centrefacial pattern. ✓
2. Malar pattern. ✓
3. Mandibular pattern. ✓

Histopathology

1. Epidermal: ↑ melanin in basal, suprabasal and str. corneum layers.
2. Dermal type: preponderance of melanophages in the superficial and deep dermis.
3. Mixed type: studies suggest an increase in the number and activity of melanocytes.

3 TYPES are known according to Wood's light examination, Epidermal (light-brown), Dermal (bluish-grey), or Mixed (dark-brown). On examination with Wood's light, epidermal melasma is accentuated but dermal melasma is not. In the mixed type, it enhances the contrast of lesions in some areas and does not in others. In patients with dark complexions (Type VI), Wood's light examination is of no benefit (inapparent type).

Types Acc to

- (1) clinical ③
- (2) Path. ③
- (3) W.L ④

centrofacial
Malar
Mandib

Etiological factors

1. Pregnancy
2. Oral contraceptives ocp's
3. Endocrine dysfunction (thyroid dysfunction)
4. Genetic factors
5. Racial factors
6. Sunlight
7. Medications (phenytoin)
8. Cosmetics

Of all these factors, genetic and sunlight exposure are the most important.

B: Melasma like pigm ?? Hydanotin

Treatment

I) Daily application of sunscreens: with SPF > 30, e.g. Spectra-ban®, Photoderm® Max.

Successful treatment of melasma involves the triad of sun-blocks, bleach & time (at least 6 months).

II) Bleaching preparations

1. Hydroquinone (HQ) 2-4% containing creams [Eldoquine® 2%, Eldoquine forte® 4%, Quinocid®, Leucodinin®, Eldopaque® 2-4% (HQ + Sunscreen)]. It is topical tyrosinase inhibitor. Higher concentration should be avoided as it may carry the risk of contact dermatitis, erythema or leukoderma.

2. Tretinoin gel, 0.05% (Retin A®) alone or with hydroquinone.

3. Azelaic acid 20% (Skinoren®): It is a naturally occurring saturated dicarboxylic acid that has demonstrated beneficial therapeutic effects in the treatment of acne and cutaneous hyperpigmentary disorders, e.g. melasma and lentigo maligna. It may arrest the progression of cutaneous malignant melanoma.

It appears to have selective effects on hyperactive and abnormal melanocytes. There are minimal effects on normally pigmented human skin, freckles, senile lentigines and nevi. The cytotoxic and antiproliferative effects of azelaic acid may be mediated via inhibition of mitochondrial oxidoreductase activity and DNA synthesis. Disturbance of tyrosinase synthesis by azelaic acid may also influence its therapeutic effects.

Azelaic acid + tretinoin proved to be more effective than Azelaic acid alone and superior to hydroquinone.

4. Kojic acid 2-4%: it acts by chelation of copper essential for tyrosinase. It is less effective than HQ.

5. N-acetyl-4-S-cyste aminyl phenol.

6. Combined preparations:

• Hydroquinone 2% + Glycolic acid 10% (MD forte bleaching gel®, Neostrata skin lightening®). Kojic acid 2% has been added in some of these combinations.

• Kligman's formula:

• Hydroquinone 2-4% (or Kojic acid 2-4%)

• Tretinoin 0.05%

• Ascorbic acid (Vit. C) 1%

• Dexamethasone 0.1%

• or Belamethasone 0.05%

Avoid the use of mono-benzyl-ether of hydroquinone as it may lead to permanent leukoderma.

7. Chemical peeling (to remove melanin): by Trichloroacetic acid 30-35%, Jessner's solution + TCA 30% or Glycolic acid (50-70%).

8. Q-switched ruby laser is not effective.

Dermal melasma does not respond to the above formulation; cover-up with opaque cosmetics is the only management option.

Becker's Nevus (melanosis)

onset: childhood or Adolescence (?? possible Role of Androgen)

CLP: unilat. macule ch By $\left\{ \begin{array}{l} \text{Hyperplasm} \\ \text{Hypertrichosis} \\ \text{Hamartoma of Sm.} \end{array} \right.$

usually $\left\{ \begin{array}{l} \text{shoulder} \\ \text{Mammary} \\ \text{Scapula} \\ \text{Extremities} \end{array} \right.$

Becker's Nevus Synd.

① over growth of:

① Underlying smooth muscles (smooth muscle hamartoma)

② adrenal glands

③ Limb, Fingers

④ scrotum

underlying
//

② Hypoplasia of: -
(under growth)

- Breast

- pectoral ms.

- Chest Wall, Spine

③ No effective (Even Laser)

??
- Q-switched
- Erbium
- Alex

2. Treat by $\left\{ \begin{array}{l} \text{Sun Protection} \\ \text{Laser Hair Removal} \\ \text{Acne. Ht.} \end{array} \right.$

D.D $\left\{ \begin{array}{l} \text{Albright's Synd} \quad (\text{since birth, CALM} \pm \text{others}) \\ \text{Giant Hairy Nevus} \quad (\text{since birth, dark}) \end{array} \right.$

Nevus spilus (speckled lentiginous Nevus)

الجلد

CALM studied \bar{e} Hyperpigmented Papules & macules (Junctional & Compound Nevus)
or with Lentigenes

Path. $\left\{ \begin{array}{l} \text{CALM Background} \rightarrow \text{melanotic Hyperpigment} \\ \text{dark spots \& Papules} \rightarrow \text{as Junctional \& Compound Nevus} \end{array} \right.$

1. Cushing

pigmentation similar to that of Addison d.t
 $\uparrow \uparrow$ ACTH & B MSH in lot of cases

2. Addison's

Hypofunctⁿ of Adrenal gland d.t either ^{Autoimmune or} IB
 $\rightarrow \downarrow$ Cortisol $\rightarrow \uparrow$ ACTH & B.MSH
S&S of Addison's

[1] General: weakness, Fatigue, wt Loss, Vomiting & Abd pain FAHM

[2] Cut.: Generalized Hyper pigm. (Brown)

- الأكنة ^{skin MM}
- Sun or light exposed areas
- Flexures
- Friction & pressure areas
- Creases of palms & Soles
- Surgical scars
- Nipple, Gums & Genitalia. CMMY

Acromegaly
pheochromocytoma . Addison's like

3. Hypert thyroidism

Many Patterns:-

- Addisonian
- Jellinek's Sign: \uparrow Eyelids pigm \rightarrow جفون غامقة
- Melasma
- Vitiligo

Pregnancy \rightarrow See specified Sectⁿ

&
OCPs \rightarrow Melasma. ✓

ACTH \rightarrow as Cushing or Addison's

RF	Facial & palmo-plantar diffuse Brown pigm. d.t ↑ MSH.
LCF <u>Hemochromatosis</u>	<p><u>Hemochromatosis</u>: AR; affect ^{liver}Heart ^{Endocrine gl}</p> <p>Hyperpig. (Bronze, blue gray or brown black) d.t excess <u>Melanin & hemosiderin</u> deposition. usually on <u>sunexposed</u> areas.</p> <p>Resemble that of <u>Addison</u>, but <u>±</u> Ass. <u>ē</u> other cut. signs as: & <u>systemic</u> as:</p> <div style="display: flex; justify-content: space-between;"> <div> <p>s. Porphyria.</p> <p>Ichthyosis.</p> <p>Alopecia.</p> <p>Nail changes.</p> </div> <div> <p>- DM</p> <p>- Hepatomegaly</p> <p>- Cardiomyopathy.</p> </div> <div> <p>- Testic. Failure.</p> </div> </div> <p><u>Diagnosis</u> ① Ferritin ② HFE gene ③ MRI of Heart & liver.</p>
<u>Amyloidosis</u>	→ Macular & papular Types
<u>Inf</u>	Kalazar, <u>Malaria</u> , <u>B</u> & <u>SBE</u> .
<u>Neoplastic</u>	<p>(1) <u>Branchogenic carcinoma</u> → <u>ACTH</u></p> <p>(2) <u>AdenoCarCinoma</u> → <u>A.N</u></p> <p>(3) <u>Lymphoma</u>:</p> <div style="margin-left: 40px;"> <p>(i) <u>Addisons</u> like <u>ē</u> ^{Hodgkins L.}Leukemia.</p> <p>(ii) Diffuse, progressive pigm. <u>ē</u> <u>MF</u>.</p> <p>(iii) <u>Cytotoxic drugs</u></p> </div>
<u>Nutritional</u>	<p>① <u>Anemia</u>: d.t deficiency of vit. B12 → <u>Mottled</u> pigm. of <u>Acral</u> areas.</p> <p>② <u>pellagra</u> ③ <u>Vit. A deficiency</u>: Xerosis + pigm.</p> <p>④ <u>Malabsorpt</u>: <u>Addison's</u> like but <u>ē out</u> <u>MM</u> affected.</p>
<u>Neurological</u>	<p>- <u>Hepatolenticular</u> degeneration, <u>stress</u>, <u>schizophrenia</u>,</p> <p>- <u>Parkinsonism</u>.</p>

Other Uses of Hyperpig.

① Drug Induced:

- Mechanism → ↑ melanin synth → OCPs
→ Deposits of drug → phenothiazines & Imipramine
Non-specific → FDE

Most Common Drugs:-

- OCPs.
- phenothiazines (sp chlorpromazine)
- Hydantoin → بالعلاج
- Antimalarial → (See AICTDs).
- Anti-Tm agents:-

- localized skin pigm → 5FU
- Nail pigm → 5FU, Bleomycin & busulfan.
- Teeth → cyclophosph. & Tetracyclines.
- Hair → MTX.

② Riehl's Melanosis: (pigmented CD)

- Diffuse or Reticulate, dark brown, slate-gray or Blue-Brown pigm. affects the face, Neck & ± Trunk
- after Contact → Tar
Cosmetic + UVL
perfumes. sp. → Forehead
Temples

الزقاة / الملتصقة

③ Erythrose peribuccale pigmentaire de Brocq:-

- red. Brown pigmentations develops around the mouth but spares a narrow perioral rim ^{منطقة} _{محاطة}
- usually affect middle age female d.t photodynamic substances in cosmetics
- DD: PIH of perioral dermatitis or ECZ.

Ceruleo derma

Q (Blue dermal Hyperpigment.)

(Blue d.t. Tyndall effect)

Melanotic

FDE.

post inflamm.
Hemochromatosis

Amyloidosis

Melasma (dermal)

Erythema dyschromicum (EOP)

Erythema ab Igne.

Incontinentia pigmenti.

Melanocytotic ⑤

○ Mongolian spot

[Nevus of Ota
N of Ito

○ Melanoma
Metastases.

○ Blue Nevi

Non melanin dermal Pigment

Alkaptonuria

ochronosis
Hemochromatosis

Drugs:

[Minocycline, Clofazimine.

Antimalarials

CPs

Gold

[Silver

• Arsenic.

• Phenothiazines.

Bleaching Creams

DNNZ.

① Hydroquinone

② Topical Retinoids

↑ Melanin loss by ↑
cell turnover
↓ Contact bet.
Ker & MCS → ↓
melanosome transfer.

③ Botanicals

plant derived

--- Tyrosinase

No toxicity

Arbutin 1% (Glycosylated HP)

glabridin 0.5% (Licorice)

Genetic acid

Nigellaamide → -- Melanosome Transfer.

Hesperidine

polyphenols.

④ Others:

Azelaic acid 20%

Kojic acid (produced
by fungus, 1-4%, ± → CD)

Mequinol (5-20%)

N-Acetyl-4

Cysteamine/phenol

N-Acetyl Glucosamine

Vit C --- TYR. enz.

⑤ Topical Cs (Mechanism)

Initial Bleaching d.t VC

↓ Cell Turnover → ↓ active MCS

↓ production of precursor steroid Hs → ↓ MSH

Anti PGs & Antileukotriene
→ -- Melanin.

Facial hyperpigmentation (Melanosis)

سوال و جواب

1. Melasma
2. Erythema dyschromicum perstans (EDP)
3. Lichen planus pigmentosus (LPP) DD L-P
4. Riehl's melanosis (RM)
5. Erythromelanosis peribuccale pigmentaire of Brocq (EPP)
6. Poikiloderma of Civatte
7. Erythromelanosis follicularis of face and neck.
8. Nevus of Ota
9. Miscellaneous causes

Et = Cosmetics, Dyes.

Face, Flexures only

No Papular lesions, No MM

30% ass. e classical L-P

- ① Risk pts:
- Genetic/Racial: dark skin individuals sp. oriental
 - UVL exposure
 - Photosensitizers: in Cosmetics.

Types of Hyperpigment ↗ clinically
→ HP
↘ Woods (See Melasma).

Miscellaneous causes:-

① Periorbital Hyperpigment. (Dark Circles) ??

- ① Familial (AD)
- pigm. dematol. lines → ② PDL (Fletcher's or Voigt's lines)
- ③ PIH (CD or AD)
- ④ shadowing from lax skin
infraorbital swelling

② Pseudo chloasma

③ AN → (Acanthosis Nigricans)

###

- ① Sunprotecta
- ② Avoid Cosmetics e photodynamic Allergens.
- ③ Bleaching Creams.
- ④ Chemical Peels
- ⑤ laser.

Hypo pigmented disorders

DD of Hypopigmented Macule ??
 (1) Albino →

Some definitions:

- Leukoderma & Hypopigmentation: Generic non specific terms used to refer to disorders ch By Lightening of skin.

① Hypomelanosis: more specific term means $(\downarrow\downarrow)$ in NL melanin pigmentation.

• Amelanosis = total lack of Melanin. (Albinism)

Depigmentation? = Loss of previously existing melanin (vitiligo).

Pigmentary dilution: Generalized lightening of skin & Hair
e.g. (Albinism)

→ Poliosis: localized whitening of hair.

↳ Cavities : Generalized " " "

امدادی سہولتیں

Classification

(See 2. \dot{r}_{max} GP)


Melano penic

Melanocytopenic

Non Melanotic

اشهرهم

↓
انستروم
Vitiqo



 ↓
 diascopy هينجن
 • Nevus edge
 anemicus

[Aebinism.
Chediak Higashi.

- PKU
- IGH

- progressive Macular Hypomelanosis

- Anemia
- oedema



Albinism

- ① Def. group of genetic disorders ch BY diffuse Pigmentary dilution d.t Partial or Total Absence of Melanin pigment in MCs of $\begin{cases} \text{Skin} \\ \text{Hair} \\ \text{Eyes} \end{cases}$ [NL No of MCs]


- ② Albinism may affect $\begin{cases} \text{Eye: ocular Albinism (OA)} \\ \text{Skin only: Albinoism} \\ \text{Skin + Eye: oculo Cut (OCA)} \end{cases}$

- ③ Inheritance $\begin{cases} \text{OA} \rightarrow \text{xLR or AR} \\ \text{OCA} \rightarrow \text{AR} \end{cases}$ (عنه)

C/P ① Cut. Manif: \downarrow color of skin & Hair \rightarrow Easy Burning & Cancer

② ocular Manif: photophobia, Nystagmus, Squint, strabismus, \downarrow Visual Acuity

A + MTAP Mutat
- AS OCA2 but \bar{e} variability in pigm.
- Common in Japan
 \swarrow OCA4



[Called TYR Negative Albinism]

[TYR Positive]

معتدل
ليس
معروف

More Common
Less Severe

OCA1: \rightarrow TYR Enz either
OCA2: \rightarrow P gene
OCA3: \rightarrow TRP1
OCA4: \rightarrow MTAP

disorders of:

Albinism ← Tyrosine

↓
Melanocyte development
Failed differentiation or
Migration of Melanoblasts
①. Piebaldism
②. Waardenburg Synd.
↓
(See Vitiligo)

↓
• Melanosome Biosynth.
① Hermansky-Pudlak Synd
② Chediak-Higashi Synd.
(See below)

↓
Melanosome Transport to KCs
(melanin-clumps in hair & skin)
↓
• Griselli Synd.

• Chediak-Higashi
others: Pit.
Alba, TVC,
Nevus depig.,
Tub. sclerosis

• Hermansky-Pudlak Synd.

هرمنسكي
لوديلاك

(AR) → ⑧ Types (1-3 Extra)

- ①. Pigmentary dilution — skin
Hair
Eye (ocular manifs similar to
OCA)
 - ②. Bleeding Tendency — NL platelet count ↓
↑↑ Bleeding Time. (BT)
 - ③. Pulmonary Fibrosis
 - ④. Granuloma
- Average life span
(30-50y)

NB: Guttate leukoderma:-

- IGH
- Vitiligo
- LS
- Arsenic
- Confetti like — TSC
HP
- planewart (Achromic)
- PVC
- PLC
- PUVA

• Diseases are diffuse / Generalized pigmentary dilution:-

- Albinism
- Hermansky Pudlak
- Chediak Higashi
- PKU
- Histidinemia
- Homocystinuria

Chediak-Higashi Synd

(AR)

30/10/19



Macro Melanosomes

Pigmentary dilution (dt Macromelanosomes)

جهاز كيروش متاخر في

Kcs ← Mcs

Pan Cytopenia.

P.N.

Pyogenic Recurrent inf. (staph.)

Cut. & sinopulmonary

31

Granulocytes = Macro lysosomal grs (Giant)

→ defective phagocytosis → inf.

Lymphohistiocytes infiltrates of L.N Spleen Liver (RES)

Death before 20 Ys.

Phenyl Ketouria (PKU)

(AR)

See diagram of melanin synth.

deficiency of phenylalanine Hydroxylase enz

ph A

2 events

ph A

tyrosine

↓ tyrosinase

Dopa

↓

Dopa 9

pheo-melanin

Eumelanin

↑ phenylalanine level in Blood

↑ Phenylalanine Metabolites

phenylpyruvate
phenylacetate

in Serum & urine

↓ @ & b

a) Competitive Inhibition of Tyrosinase
 b) ↓ Conversion to Tyrosine
 "cut. Pigm dilution"

CIP of PKU



o Culo Cut. Pigmentary
dilution $\left\{ \begin{array}{l} \text{Fair Skin} \\ \text{Blond Hair} \\ \text{Blue Eye} \end{array} \right.$

- ① MR
- ② Seizures
- ③ Hyporeflexia

• Microcephaly
• Epicanthus
• Syndactyly

↓
Skin fold of upper eye-lid
Cover inner corner of eye

Atopic like ECZ

Scleroderma like lesions

(Pseudo scleroderma).

④ Bromhidrosis \rightarrow offensive odour of sweat

Diagnosis ① $\uparrow\uparrow$ Serum phenylalanine level $\geq 15 \text{ mg/100mL}$ (Diagnosis)

② Early diagnosis in Infancy: (Ph.A. level \pm NL)

Urine + 5% Ferric chloride \rightarrow green discoloration
(dit \uparrow ph. pyruvate level)

ochronosis
porphyria

Exd

: Diet low in ph. Alanine; if started early \rightarrow prevent MR (Not the Cut. Manifs).

NB : 3 Inherited disorders of aa. Metabolism that \pm ass. \bar{e} Melanopenic Hypomelanosis

$\frac{3}{1} \frac{1}{2} \times$
AA

① PKU: \rightarrow defective metabolism of phenylalanine

② Histidinemia: \rightarrow defective Histidine.

[Hypopigm.
MR

③ Homocystinuria: defective Methionine

[Hypopigm. - CNS & skeletal
Thrombembolism.

Progressive Macular Hypomelanosis

Common in young Women residing in Tropical climates (18-25)

(CLP) → Asymptomatic, ill defined, Nummulars, non scaly, Hypopigmented macules & patches on the Trunk (Rare) affecting proximal Ext. & Face:

Buttock's لونزيت

(MF)

بالقبة (TVC) → usually ^{no} diagnosed & treated as TVC

##

Topical -
Clindamycin +
Benzyl Peroxide
+
UVA

Histopath:

↓ melanin

EIM: < uninvolved skin: Large melanosomes
involved skin: Small melanosomes bound to memb.

AET: unknown; ± d.t. (P. Acnes)

Idiopathic Guttate Hypomelanosis (IGH)

Also

Acq. leukoderma ch BY

[0.5 - 5 mm
pin sized

- Age > 40 yrs
- usually females or
- usually darker skin patients
- chic sites: shin & extensor of forearms

(CLP) → 0.5 - 5 mm Well defined, (Porcelain) white macules & smooth (Not atrophic surface)


(No) < Coalescence.
Spont. Resolut.

- Vellous hair in lesions usually retain its pigment.

(##) → No consistently effective tt; a variables ±:

- ① ILs Reassurance
- ② Cryo (in 1 study complete repigm. in 90%)
- ③ Minigrafts
- ④ sun protecta

Sun light
لغيبا
السبب



Vitiligo

Dr. Hany Abo Alwafa

(2015)

VITILIGO

Vitiligo is a common, idiopathic, acquired, circumscribed hypomelanotic/amelanotic skin disorder caused by inactivation or destruction of melanocytes in epidermis and hair follicle and characterized clinically by milky white patches of different sizes and shapes (depig)

❖ **EPIDEMIOLOGY:** Incidence: 1-2% of general populations, Age: any age, but 50% of cases occur before 20 Sex: M=F • Congenital Vitiligo is rare (1?)

❖ **ETIOPATHOGENESIS:** (Still unknown): 6 theories

XX MCs

① ➤ Genetic theory: inheritance is polygenic, 10-20% of cases show +ve FH

② ➤ Autoimmune theory: Evidence: frequent co-occurrence of autoimmune diseases in these patients and their relatives, such as SLE, psoriasis, AA, halo nevi and mainly autoimmune thyroid diseases, besides the favorable response to immunosuppressive therapies

بجانب مع
امراض اخرى

HI
IgG → TRP1,2 1- Humoral immunity: Antibodies against melanocyte antigens (Tyrosinase, tyrosinase-related proteins 1 and 2; TRP1,2) → MCs destruction

CMI
↑ CD8
↓ Treg 2- Cell mediated immunity: The high frequencies of melanocyte-reactive cytotoxic T cells (CD8⁺) in the peripheral blood of patients with vitiligo, perilesional T-cell infiltration and melanocyte loss

- Decreased regulatory T cells activity (Tregs. maintain peripheral tolerance through the active suppression of self-reactive T-cell activation and proliferation).

عناصر ما يلاحظ
نفسه

③ ➤ Neural Theory: Segmental vitiligo often occurs in a dermatomal pattern. This observation led to a neural hypothesis that proposes that melanocyte destruction in vitiligo is caused directly or indirectly by an inappropriate reaction of the melanocytes to certain neurochemical mediators as neuropeptides, catecholamines or their metabolites, that is secreted from nearby nerve endings.

④ ➤ Autocytotoxic (Self-destruct) theory: Toxic metabolites, either from environmental exposures, such as phenol or quinones, or from intrinsic melanin synthesis pathways, may accumulate and damage melanocytes of genetically susceptible individuals.

Ext
Int

Toxidants
(Ros)
↓ Antioxidants

⑤ ➤ Oxidative theory: Accumulation of free radicals toxic to melanocytes (as hydrogen peroxide: H₂O₂) together with decreased level of antioxidant enzymes as catalase, superoxide dismutase, & glutathione peroxidase → oxidative stress → MCs destruction.

Ros

⑥ ➤ Adhesion defect (melanocytorrhagy) theory

The main clinical sign reinforcing this theory is the occurrence of koebnerization or Koebner phenomenon. It has been suggested that adhesion defects

are involved in the disappearance of melanocytes in vitiligo lesions. Mechanical Trauma → MCs detachment & transepidermal loss.

- ⑦ ➤ **Convergence Hypothesis** : Loss of melanocytes in vitiligo appears to occur through a combination of several mechanisms that act in concert.

❖ CLINICAL FEATURES

The most common form of vitiligo is a ~~totally amelanotic macule (or patch)~~ surrounded by normal skin. The color is usually uniformly milk or chalk-white. Usually, vitiligo is asymptomatic, but occasionally the involved skin may be pruritic.

Although may occur anywhere on the body, there are characteristic patterns of involvement. The most common sites of involvement are areas subjected to repeated trauma or pressure (Koebner) such as elbows, knees, digits, flexor wrists, dorsal ankles and shins, as well as sites of repeated friction such as the body folds (i.e. the axillae, anogenital area). Typically, facial vitiligo occurs around the eyes and mouth (i.e. periorificial). In acrofacial vitiligo, periungual involvement of one or more digits may be associated with lip depigmentation; however, the latter can be an isolated finding.

• Sites:

- ① Trauma sites
- ② periorificial
- ③ Lip-tip
- ④ Hair { localized
diffuse

Hair is usually spared and remain pigmented, but in some cases hair depigmentation (leukotrichia) may also occur simultaneously. In the scalp, vitiligo usually leads to localized patches of grey or white hair, but total depigmentation of the scalp hair may occur. Depigmented body hair within vitiligo macules are considered as markers of poor repigmentation prognosis.

poliosis

diffuse

➤ Clinical types of vitiligo

Vitiligo	Subtype
Non segmental vitiligo (NSV)	<ul style="list-style-type: none"> Acrofacial Mucosal (more than one mucosal site) Generalized (<i>Vulgaris</i>: multiple areas in symmetrical pattern) Universal (80-90% of BSA) Mixed (associated with SV) Rare variants
Segmental vitiligo (SV)	Uni-, bi-, or pleurisegmental
Undetermined/unclassified vitiligo	Focal Mucosal

A- **Non-segmental vitiligo** : Clinically, NSV is characterized by depigmented macules that vary in size from a few to several centimeters in diameter, often involving both sides of the body with tendency toward symmetrical distribution. Contrary to SV, in NSV, body hairs are usually spared and remain pigmented, although hair depigmentation may occur with disease progression. Types : see above.

Rare variants: (Guttate, Follicular, inflammatory, Multichrome, occipital)

✓ *Vitiligo punctuate (Guttate)*: punctiform 1- to 1.5-mm macules.

✓ *Vitiligo minor*: The disease seems to be limited to dark-skinned individuals. The term 'minor' refers to the partial defect in pigmentation. The differential diagnosis from early stage cutaneous lymphoma is of primary importance, and repeated biopsies with molecular studies of clonality may be needed (Passeron & Ortonne, 2010).

✓ *Follicular vitiligo*: primary involves the follicular reservoir with limited skin involvement.

✓ *Inflammatory Vitiligo*: The lesions could sometimes have a raised red border. A mild pruritus could be associated. الحكة

✓ *Multichrome Vitiligo*: This form of vitiligo is mostly seen in darker phototypes. Within a vitiligo lesion, areas of depigmentation coexist with hypopigmented areas and with normal color as in surrounding skin. In the hypopigmented area, a partial loss of melanocyte is observed. Trichrome vitiligo is commonly used to describe this pattern, but various degrees of hypopigmentation can be observed leading to trichrome, quadrichrome, or pentachrome vitiligo.

✓ *Occupational/contact vitiligo*: The terms 'contact' or 'occupational vitiligo' have been used to describe a distinct form of vitiligo induced exposure to certain chemicals phenols and catechols.

B- SEGMENTAL VITILIGO (SV): One or more white de-pigmented macules distributed on one side of the body, usually respecting the midline, early follicular involvement (leukotrichia), and rapid development over a few weeks or months, and overall protracted course.

Segmental Vitiligo (SV)	Nonsegmental Vitiligo (NSV)
<ul style="list-style-type: none"> - Often begins in <u>childhood</u> - Has rapid onset and <u>stabilizes</u> - Involves <u>hair</u> compartment soon after onset - Is usually <u>not</u> accompanied by other autoimmune disease - Often occurs on the <u>face</u> - Is usually responsive to <u>autologous grafting</u>, with stable repigmentation (Early, stable, hair, surgery) Not associated 	<ul style="list-style-type: none"> - Can begin in childhood, but <u>later onset</u> is more common - <u>Progressive</u>, with flare-ups - Involves <u>hair</u> compartment in <u>later</u> stages - Is often associated with personal or family history of autoimmunity - Commonly occurs in sites sensitive to pressure and friction and prone to trauma - Frequently <u>relapses</u> in situ after autologous grafting (Late, progressive, hair, late) Not cured after grafting

D- UNDETERMINED/UNCLASSIFIED VITILIGO

- *Focal vitiligo*: isolated hypopigmented lesion that does not fit a typical segmental distribution, and which has not evolved into NSV after a period of 1-2 yr.

- *Mucosal vitiligo*.

VITILIGO-ASSOCIATED COMORBIDITIES : Vitiligo is not only a disease of melanocytes of the skin. Human melanocytes are derived from the neural crest and are located on various parts of the body. Some authors underline the fact that vitiligo is the skin manifestation of an internal disease.

• Thyroid
Ocular

1- Vitiligo and autoimmune disorders

Generalized vitiligo is frequently associated with other autoimmune diseases, particularly autoimmune thyroid diseases (Hashimoto's thyroiditis and Graves' disease) and antithyroid antibodies (30% مهمة جدا والافضل تتعامل مع كل المرضى), rheumatoid arthritis, adult-onset type 1 diabetes mellitus, psoriasis, pernicious anemia, systemic lupus erythematosus, and Addison's disease.

- Anti thyroid Abs
- Anti Microsomal

2- Vitiligo and ocular diseases

The uveal tract and retinal pigment epithelium contain pigment cells. The most severe form of uveitis is seen in the Vogt-Koyanagi-Harada syndrome. This syndrome is characterized by vitiligo, uveitis, aseptic meningitis, dysacusis, tinnitus, poliosis, and alopecia.

Alezzandrini syndrome: includes facial vitiligo, poliosis, deafness, and unilateral visual changes. The affected eye has decreased visual acuity and an atrophic iris.

❖ Histopathology:

Microscopic examination of involved skin shows a complete absence of melanocytes in association with a total loss of epidermal pigmentation. Superficial perivascular and perifollicular lymphocytic infiltrates may be observed at the margin of vitiliginous lesions, consistent with a cell-mediated process destroying melanocytes. Degenerative changes have been documented in keratinocytes and melanocytes in both the border lesions and adjacent skin. Other documented changes include increased numbers of Langerhans cells, epidermal vacuolization, and thickening of the basement membrane. Loss of pigment and melanocytes in the epidermis is highlighted by Fontana-Masson staining and immunohistochemistry testing.

①
② Edge
③
④
⑤
⑥
⑦
⑧
⑨
⑩
⑪
⑫
⑬
⑭
⑮
⑯
⑰
⑱
⑲
⑳
㉑
㉒
㉓
㉔
㉕
㉖
㉗
㉘
㉙
㉚
㉛
㉜
㉝
㉞
㉟
㊱
㊲
㊳
㊴
㊵
㊶
㊷
㊸
㊹
㊺
㊻
㊼
㊽
㊾
㊿

❖ DIFFERENTIAL DIAGNOSIS OF VITILIGO

i- Differential diagnosis of non-segmental vitiligo (NSV):

Diagnosis	Features
- Inherited or genetically induced hypomelanoses	
Piebaldism	White forelock, midline depigmentation of anterior body, bilateral shin depigmentation; autosomal dominance
Tuberous sclerosis	Small or larger (ash-leaf) white spots, seizures, typically later appearance of other cutaneous symptoms (e.g., shagreen patches, angiofibromas); autosomal dominance
Ito's hypomelanosis	Linear distribution, unilateral or bilateral pattern of hypopigmented streaks; sporadic; chromosomal or genetic mosaicism (involving blood or skin cells)
Waardenburg's syndrome	White forelock, hypertelorism, deafness (varies according to genotype); possible association with congenital megacolon (Hirschsprung's)

	disease)
- Postinflammatory hypopigmentation: Occurs in inflammatory disorders accompanied by increased epidermal turnover (e.g., psoriasis, atopic dermatitis), in lichenoid-cytotoxic infiltration of epidermal basal layer (e.g., lichen planus, toxic drug reactions), and in scleroderma; clinically distinguished by identification of the primary skin disease (e.g., scalp or plaque psoriasis, flexural dermatitis for atopic dermatitis, scleroderma plaques), but may coexist with primary disease; in genital areas, lichen sclerosus may resemble vitiligo or be associated with true vitiligo; biopsy is useful in cases that are difficult to diagnose	
- Paramalignant hypomelanoses	
Mycosis fungoides	May present with skin depigmentation in dark-skinned patients; clinical diagnosis may be difficult in the absence of signs of inflammation and skin infiltration; biopsy results are diagnostic
Melanoma	Vitiligoid changes range from halo of depigmentation around a cutaneous melanoma (malignant Sutton's phenomenon) to more widespread vitiligoid changes; under Wood's lamp, the margins of such vitiligoid lesions are usually less distinct than in common vitiligo, and depigmentation is usually incomplete

- Parainfectious hypopigmentation	
Tinea versicolor	Can cause vitiligoid changes, generally after treatment in the absence of re-exposure to UV light; the distribution and shape of the lesions and the presence of scaling and yellow fluorescence of untreated lesions allow a definite diagnosis
Indeterminate leprosy	Manifested as hypochromic patches that are hypoesthetic to light touch
- Progressive macular hypomelanosis: Seen in young adults and frequently referred to as a recalcitrant pityriasis versicolor; white macules are present on the trunk, with more marked involvement on the lower back and axillae; <i>Propionibacterium acnes</i> is a suspected cause of depigmentation	
- Post-traumatic leukoderma: May occur after deep burns or scarring in which hair follicles are removed entirely or in which the bulge area containing melanocyte precursors is destroyed; can be difficult to distinguish from true vitiligo when scarring is not obvious; may also occur after toxic epidermal necrolysis	
- Occupational and drug-induced depigmentation	
Occupational	A subtype of vitiligo triggered by occupational exposure, which evolves from contact depigmentation (generally caused by a phenolic-catecholic derivative*) to a generalized phenomenon; may be difficult to distinguish from other cases of vitiligo
Drug-induced	Can result from use of systemic drugs (e.g., chloroquine, fluphenazine, physostigmine, imatinib); in rare cases topical imiquimod may also cause vitiligoid depigmentation

ii- Differential diagnosis of segmental vitiligo (SV):

- *Nevus depigmentosus*(ND): (*Achromic Nevus*):

Nevus depigmentosus is a congenital pigmentary disorder. The disease is primarily limited to the skin though there are reports of association of neurological abnormalities and limb hypertrophy. The commonly used clinical diagnostic criteria are as follows:

- Leukoderma present at birth or of an early onset.
- No alteration in the distribution of leukoderma throughout life.
- No alteration in texture or change in sensation in the affected area.
- Absence of hyperpigmented border.

DD
1. at or shortly after birth
2. Stable
3. W. L. 4. Bio

Nevus depigmentosus is generally classified as isolated, segmental, and whorled types. Wood's lamp examination shows an "off-white accentuation" in ND as compared to the chalky white accentuation in the case of vitiligo. The lesion usually contains a normal or subnormal number of melanocytes compared with control perilesional skin, but the production of melanin pigment is reduced. Sun exposure may attenuate the difference in pigmentation from normal skin. In difficult cases, a biopsy is needed to differentiate naevus depigmentosus from SV.

- *Hypomelanosis of Ito*: is a rare neurocutaneous syndrome characterized by hypopigmented skin lesions with a peculiar pattern of streaks, whorls, swirls and patches. The associated systemic abnormalities predominantly affect the nervous and musculoskeletal system and less commonly gastrointestinal, renal, and cardiac systems.

A solitary white macule or several white to off-white macules often present a challenge because they may be the presenting stage in the evolution of any of the processes listed above. In some instances, a biopsy may be helpful, but standard histologic studies cannot distinguish a vitiligo macule from one of chemical leukoderma, piebaldism, or Waardenburg's syndrome. Biopsy is useful to establish diagnoses such as lupus erythematosus, leprosy, and tinea versicolor. The presence of melanin or melanocytes in a biopsy cannot be assumed to exclude a diagnosis of vitiligo because trichrome vitiligo, perilesional skin, and repigmenting macules of vitiligo also demonstrate melanocytes.

Naevus depig

Failure of Melanosome transfer

H/p edge

- degenerate Kc, Mc
- depigmentation (Center)
- inflam in Pitt
- ↑ Lcs

TREATMENT OF VITILIGO**➤ Introduction**

Treatment of vitiligo is aimed at stopping the disease progression and restoring the loss of melanocytes in the lesions. No single therapy for vitiligo produces predictably good results in all patients; the response to therapy is highly variable.

Recovery of vitiligo is initiated by proliferation, migration and melanogenesis of melanocytes still present in the hair follicle units (perifollicular pattern of repigmentation), in the margins of vitiligo lesions or spared epidermal melanocytes within the achromic lesions.

In general, patients with a family history of vitiligo, mucosal involvement, a positive Koebner response, and the NSV subtype of vitiligo tend to have progression of their condition in the absence of therapy. The best response to treatment is seen in younger patients, disease of recent onset, darker skin types, and in lesions on the face, neck, and trunk. Distal extremities tend to be extremely refractory to non-surgical modalities.

❖ Treatment of vitiligo can be classified into :

- A- Medical treatment
- B- Photo(chemo)therapy
- C- Laser therapy
- D- Antioxidants
- E- Surgical Treatment
- F- Depigmentation Therapy
- G- Camouflage
- H- New concepts in treating vitiligo

➤ MEDICAL THERAPY

1- Systemic corticosteroids (CSs): Systemic steroids can arrest the activity of the disease, but are not effective in repigmenting stable vitiligo. Oral minipulse therapy of betamethasone/dexamethasone 2.5-10mg on 2 consecutive days per week for 3-6 months has been pioneered in India. Moreover, side-effects associated with long-term use of daily systemic corticosteroids contraindicate their common use.

2- Topical corticosteroids: Topical steroids are the most clinically effective choice for topical therapy and often first-line therapy, especially in children or for localized disease. Moderately potent to potent topical corticosteroids are used. However, vitiligo requires prolonged use of these agents, often much longer than the usual "safe" recommended periods of use for inflammatory dermatoses. This results in significant, therapy-limiting side-effects like atrophy, hypertrichosis and peri-lesional hypopigmentation.

Doses of 50 gm or less per week of clobetasol propionate 0.05% during a period of 12 weeks are safe on adult vitiligo patients, although local side effects are possible. Topical all-trans-retinoic acid (tretinoin) prevents skin atrophy induced by long-term use of topical corticosteroids, without abrogating their anti-inflammatory effects.

1. Aim

2. No single therapy

3. Variable response

4. Pattern of Repigment

5. prognosis

good prognosis

1. اصول
2. ديتا
3. كل ضحية
4. وجبة
5. ملعة 7 شهور

if progressing

فترة
طويلة

3- Topical calcineurin inhibitors (TCI): TCI (tacrolimus & pimecrolimus) can be to selected areas, in particular the head and neck region to avoid SE of topical Cs. Compared to topical corticosteroids, TCI produce slightly inferior to equivalent repigmentation rates, but the effect occurs earlier in the course of treatment.

4- Topical vitamin D₃ analogs : Topical calcipotriene (a vitamin D₃ analogue) is sometimes used for localized disease, but trials have indicated that it has limited or no effect when used alone and that it results in at most a minor increase in repigmentation when used in combination with ultraviolet radiation or topical corticosteroids. Calcipotriene 0.005%/betamethasone dipropionate 0.05%- 0.064% ointment is effective and well tolerated in the treatment of patients with vitiligo. Adult and pediatric facial vitiligo patients may see repigmentation as early as 2 months after initiation of therapy.

➤ PHOTO(CHEMO)THERAPY

Ultraviolet light has been used to treat patients with vitiligo since the 1800s. The exact mechanism of action is unknown; it is believed to have both immunosuppressive and melanocyte stimulatory effects (migration and proliferation).

Phototherapy induces a predominantly perifollicular pattern of repigmentation, whereas topical agents exhibit a diffuse type, acting synergistically when combined.

1- Ultraviolet A (UVA) Phototherapy

- ✓ **Systemic (oral) PUVA:** PUVA is approved by the Food and Drug Administration (FDA) for the treatment of vitiligo. Psoralen photochemotherapy involves the use of psoralens combined with UVA light. For oral PUVA, 8-methoxypsoralen (8-MOP; 0.6–0.8 mg/kg), 5-methoxypsoralen (5-MOP; 1.2–1.8 mg/kg) or trimethylpsoralen (0.6 mg/kg) is given orally 1–3 h before exposure to UVA. The best results from PUVA can be obtained on the face, trunk, and proximal parts of the extremities. However, 2-3 treatments per week for many months are required.

۳-۲ ل
قبل ایست
۳-۱ ساعت

cataract
liver enz

افضل باي

- ✓ **Topical PUVA:** a thin coat of 8-MOP cream or ointment at very low concentration (0.001%) should be applied 30 min before UVA exposure. The main disadvantages are severe blistering reactions, perilesional hyperpigmentation and lack of effectiveness in limiting the progression of actively spreading vitiligo.

- ✓ **Khellin UVA (KUVA):** Another photochemotherapy regimen. KUVA consists of khellin as the photosensitizer (furanochrome extracted of the plant Ammi visnaga and UVA). KUVA's lack of phototoxicity makes it safe for use as a home treatment or treatment with natural sunlight, even in a daily regimen. It is also less mutagenic than psoralens and it promotes less darkening of normal skin.

2- Narrow-band ultraviolet B (NB-UVB):

vitiligo 0.15% BSA
spread 2

NB-UVB is indicated for generalized NSV. Total body treatment is suggested for lesions involving more than 15–20% of the body area. Total NB-UVB has also

been considered as treatment for active spreading vitiligo, even if limited supportive data are available. Many therapists tend to stop irradiation if no repigmentation occurs within the first 3 months of treatment or in case of unsatisfactory response ($< 25\%$ repigmentation) after 6 months of treatment. Phototherapy is usually continued as long as there is ongoing repigmentation or over a maximum period of 1 or 2 years. Maintenance irradiation is not recommended, but regular follow-up examinations are suggested for detecting relapse.

Compared to PUVA, NB-UVB is found to be superior to PUVA due to various reasons including better repigmentation, stabilization and color match with natural skin, a better safety profile as it maximizes the delivery of narrow-band UVB radiation in the range of 312-313 nm which is the most beneficial of the UV spectrum, while minimizing exposure to superfluous UV radiation thereby considerably decreasing the risk of severe burning or pathogenic exposure to UV in harmful ranges. It also avoids the adverse side effects of the psoralens used in conventional PUVA therapy. As UVB treatment requires no supplemental drugs and is considered to be effective and safe in children and pregnant women. There is no need for post treatment eye protection as should be done with PUVA.

NB-UVB > PUVA

(1) Better

• Repigm.
• Stabilizat
• Color match

(2) Safer:

• No psoralen
• No phototoxicity
• No risk of liver damage
• No risk of cataracts

➤ **LASER THERAPY:** NB 311 - 315. Excimer laser is relatively safe and effective for localized disease. UV-sensitive areas respond best as well as a short duration of the disease. More frequent treatments achieve better results. Compared to other treatment modalities, the excimer laser most likely constitutes the treatment of choice for localized vitiligo.

➤ **ANTIOXIDANTS:** Pseudocatalase, vitamin E, vitamin C, ubiquinone, lipoinic acid, *Polypodium leucotomos*, catalase/superoxide dismutase combination, and *Ginkgo biloba* are antioxidants that have been used alone or, more frequently, in combination with phototherapy. The administration of antioxidants during or before phototherapy aims to counteract the oxidative stress induced by UV radiation itself, increasing its effectiveness.

~ (Ros)

Catalase and superoxide dismutase are enzymes with antioxidant properties. They are available in a combination topical medication marketed outside of North America as "Vitix" 400 LE / localized / once - 2 times

➤ SURGICAL REPIGMENTATION THERAPY

Surgical alternatives exist for the treatment of vitiligo; however, because of the time-consuming nature of surgical therapies, these treatment regimens are limited to segmental or localized vitiligo. Unilateral (segmental) vitiligo has been shown as the most stable form, responding well to surgical interventions in numerous studies. Such areas as dorsal fingers, ankles, forehead, and hairline tend to not repigment well. Patients who have small areas of vitiligo with stable activity are candidates for surgical transplants. The most important factors indicating stability are as follows:

- No progression of lesions for at least 2 years.
- Spontaneous repigmentation indicates vitiligo inactivity.

- A positive minigrafting test disclosing repigmentation at 4-5 minigrafts, which, to date, is the most accurate evidence of vitiligo stability.
- Absence of new koebnerization, including the donor site for the minigrafting test.
- Unilateral vitiligo is the most stable form of vitiligo (SV)

- Types of surgical therapy:

I- Tissue Grafting:

- **Minigrafting (punch Grafting):** In this method, grafts are harvested with the help of biopsy punch, preferably from the gluteal region, and fixed into the pits created by a similar instrument to the recipient area. They are secured with micropore tape or steri strips. Dressing is removed after 7-14 days.
- **Split thickness skin grafting:** This method uses skin grafts harvested with either a hand-held Humpy's knife and placed directly on the recipient area prepared by laser ablation or motorized dermabrasion. They are secured with surgical dressing, which is removed after 1 week.
- **Suction blister grafting:** Epidermal grafting involves obtaining pure viable epidermis-bearing melanocytes in the form of blisters by applying negative pressure (300-500 mmHg) to the normally pigmented skin. The grafts thus obtained are transferred to the denuded recipient sites. Suction Blistering Epidermal Graft is one of the most efficient and successful surgical modalities.

II- Cellular Grafting (Noncultured & Cultured Techniques):

These techniques use separated cells in the form of suspension. These cellular suspensions are transplanted as noncultured suspension or after culturing them *in vitro* on to the recipient area. The major advantage of these suspension and culturing techniques is that, they permit treatment of affected skin manifold larger than the donor area (van Geel et al., 2011).

- **Noncultured melanocyte-keratinocyte transplantation:** After the achromic epidermis is removed, an epidermal suspension with melanocytes and keratinocytes previously prepared by trypsinization of normally pigmented donor skin is spread onto the denuded area and immediately covered with nonadherent dressings
- **Cultured-melanocyte transplantation:** Depigmented skin is removed using liquid nitrogen, superficial dermabrasion, thermosurgery, or carbon dioxide lasers; very thin sheets of cultured epidermis are grafted or suspensions are spread onto the denuded surface.

- **Stem Cells:** Grafting of Stem / Reservoir MCs in pulse area of ORS of HI

DEPIGMENTATION THERAPY

This treatment should generally be reserved for adults who have severe vitiligo with > 50% depigmentation (or) extensive depigmentation on the face or hands that cannot be repigmented or for adults who choose not to seek repigmentation and can accept the permanence of never being able to tan.

Monobenzyl ether of hydroquinone (MBEH) is the mainstay and FDA approved to depigment and is associated with local side effects and risk of repigmentation. Other agents which are also used are 4-methoxy phenol and 88% phenol. Physical therapies for depigmentation include Q-switched ruby and alexandrite lasers and cryotherapy. Second-line agents which can be explored for depigmentation include imatinib mesylate, imiquimod, and diphencyprone.

MBEH
(phenol)

- **CAMOUFLAGE** : There is a wide choice of self-tanning agents, stain- dyes, whitening lotions, tinted cover creams, compact, liquid and stick foundations, fixing powders, fixing sprays, cleansers, semipermanent and permanent tattoos, and dyes for pigmenting facial and scalp white hairs. Permanent camouflage, micropigmentation and tattoos should be considered with particular caution, due to the unpredictable course of the vitiligo.

❖ CHOICE OF TREATMENT

Each therapeutic modality should be tried for a sufficient period of time as initiation of pigmentation varies and is in general rather slow. An effective therapy should be continued as long as there is improvement or the lesions completely repigment.

other lines: -

- 5 Fu + Dermabrasion
- PRP

[$\frac{1}{2} \frac{d}{dt} \left(\frac{1}{2} \frac{d}{dt} \right)$]

- WS3: limb defekt
- WS4: assē Hirschsprünge

Neutrophilic Dermatoses

Def. Inflammatory dermatoses char. histopathologically by predominant Neutrophilic Infiltr. in absence of Infection & Vasculitis

show prompt response to CS.

Epid.

Dermal

- [pustular ps.
 - [AGEF
 - [SCPD
 - [IgA pemphigus < دفين
 - [Infantile Acropustulosis
 - [Transient neonatal pustular Melanosis (TAPM)
 - [Keratoderma hemorrhagicum
 - [Amicrobial pustulosis of folds.
- (♀ & ♂ chr. pustulosis of folds, EAC, scalp + CTDs.)

with Vasculitis

يقوى دالة
Vasculitis

1. Small V V.
2. Med. V V
3. large V V

without Vasculitis

+/- Vasculitis

- Sweet Synd.
- PG
- Behcet
- BADAS
- Neutrophilic Eccrine Hidradenitis
- Rheumatoid neutrophilic dermatitis
- SAPHO synd
- Neutrophilic urticaria?
- Sholl's dis
- Periodic fever synd.
- Bullous dis:

• pustular Vasculitis of dorsal Hands.

3 neut -> urtic Eccm Rheum.

All HL

قوي
"Neutrophilic urticaria"

- [DH
- [LAD
- [BSLE
- [EBA (inflammatory type).

(Sweet Syndrome)

(5)

Def: Commonest ND (prototype of all ND).

Epidemiology: Age: Typically → 30-50y.

Some cases → neonates < 5 days.

Sex: 1. Classical Type → M:F = 1:1.4 2. Mq & child hood Type: M=F

Criteria كلف
جيدا ولفع لا صان
طب CIP زود
للها

زيادات:

A. Systemic Prodroma

- FAHM
- Arthralgia
- Myalgia
- CNS (Psychosis, Migraine, Si Zunes)

- Pulm.
- GIT, Bone & renal.


B. Cut. زيادات:

oral & ocular
ulcerate Inflamm
(more e Mg)


Course: Exacerb.
& remission.

Recurrence:
30-50%
(classic) (Mg)

No Scarring



Minor Criteria



2. Fever > 38°C & Malaise.

3. Lab Findings (≥ 3)

- ESR > 20
- +ve CRP
- Leukocytosis > 8000
- > 70% Neutrophils

4. Excellent response to CS or KI.

For diagnosis
2 Major +
2 Minor.

Treatment

CS ← الخلاص الاساسي ①

(0.5-1 mg/kg/d For 4-6 wks)

② بعد اسبوع

KI (900 mg/d)

• Dapsone (100-200 mg/d)

• Colchicine (1.5 mg/d)

• NSAIDs; Indomethacin.

دكن تذكر ان هذا المرض:

① Bg condition; If untreated it will remain chronic ^{مزمن}

② Cut. lesions → involute but scarring (5-12 wks) ^{تجرب}

③ Recurrence: ^{تكرار}

• classical case → 30% (Even if treated)

• Mg ass. n → 50%

④ That URTI

سؤال امتحان ?? Mg Sweet

NB:

Characteristic features of malignant/associated Sweet's syndrome

1. No ^{Sex: Predisposed (M=F)}
URTI

2. Blood: • Anemia
• Thrombocytopenia
• -ve Neutrophilia in $\geq 50\%$

3. lesion: • Before Mg (60%)
• Severe wide spread.
• Bullous or ulcerative & oral mm. affect-
• Highly recurrent ($\leq 50\%$) & often herald Tm relapse.

Acute febrile neutrophilic dermatosis is a misnomer?

- Chronic recurrent forms exist.
- Fever and neutrophilia are variable features.
- Extracutaneous manifestations are common.

Types of Sweet's

1. Classical (Idiopathic) (70%)

2. Localized: (FEG dorsal Hands (NVDH))

3. Mg. associated (10%)

4. Inflamm. dis. Associated (Infer AICTDs)

5. pregnancy ass.



Pyoderma Gangrenosum

Etiopath. = Associate
Criteria For Dx (100%)
Types
HP & TP

For diagnosis: 2 Major + 2 Minor

رجف جراحيا
وده اقم حاجية

Major criteria (both required) or 50% ↑ in size in 1m.
1. Rapid (usually > 1 cm/day) progression of painful necrolytic ulceration with an irregular, undermined, violaceous border, usually with a preceding papule, pustule or bulla, and pain out of proportion to the size of the ulcerated area.

Minor criteria (at least 2 required)
1. (a) history of pathergy, or (b) presence of cribriform scarring. *Atrophic.*
2. Presence of a disease known to be associated with PG (IBD, polyarthritis, myelodysplasia, leukaemia, monoclonal gammopathy).
3. Appropriate histopathological findings.
4. Rapid response to oral corticosteroid therapy (usually interpreted as at least 50% reduction in size using 1-2 mg/kg/day). within 1m.

pen
size
comp

Classification of PG

Morphologically			
Ulcerative (Typical) Frequent	Bullous Frequent	Pustular Frequent	Vegetative Uncommon
Arthritis, IBD, monoclonal gammopathy	Hematologic dyscrasias/ Malignancy	IBD	No systemic associations/ Chronic renal impairment
Lower limbs (Pre-tibial)	Upper limbs	Face and trunk	Trunk

?? HG or PG
mg: actual work
6. genital
7. orp
8. peristom
9. Extolcut.
10. Childhood oral & genital.

(IAG)
IgA
Benign

30 IBD: 20-30
20 Arthritis: Rh. or sero-neg (20%)
15 IgA: 15% (plasma cell dyscrasia)

Clinical types	Histopathology
Ulcerative [Figure 5]	Edema, neutrophilia Secondary lymphocytic vasculitis
Bullous	Epidermal necrosis with neutrophils, subepidermal bulla
Pustular	Epidermal and dermal neutrophilia
Vegetative	Neutrophilic and eosinophilic and histiocytic mixed infiltrate. Intra- and subepidermal granuloma formation

Treatment
(مفاتيح حادثة في حالة)
أول
↓
Best is Cs
(Topical & Syst)
others
IL Cs
[Tacrolimus
Dapsone
[Lamprolone
[Sulfa Salazn
MTX
[Cyclosporin
Thalidomide
4

Associations → 7
4 IBD
Arthritis + 3
IgA gamm
Ma (leukemia)
PAPA: P, Yog. Arthritis, PG & Acne.
PASH: PG, Acne, S. Hidradenitis.
PAPASH: PAPA + Supp. Hidradenitis.

تحتفظ الجداول جيداً
ثم بعد ذلك يقرأ
التفاصيل

Behcet Disease

(Oculo-oral genital synd.)

-Diagnostic criteria according to ISG (International study group for Behcet's Disease .1990)

Criterion	Required features
Recurrent oral ulceration	Minor aphthous, major aphthous, or herpetiform ulceration observed by physician or patient, which recurred at least 3 times in one 12-month period
Plus any two of the following:	
Recurrent genital ulceration	Aphthous ulceration or scarring, observed by physician or patient
Eye lesions	Anterior uveitis, posterior uveitis, or cells in vitreous on slit lamp examination; or Retinal vasculitis observed by ophthalmologist
Skin lesions	Erythema nodosum observed by physician or patient, pseudofolliculitis, or papulopustular lesions; or Acneiform nodules observed by physician in postadolescent patients not on corticosteroid treatment
Positive pathergy test	Read by physician at 24-48 h.

مراجعه

2- مهم جداً "لا حرج"

BRUX

International criteria for the diagnosis of Adamantiades-Behçet disease (2014) (9)

- Recurrent oral aphthous ulcers 2
- Skin lesions (papulopustules, erythema nodosum, thrombophlebitis) 1
- Vascular involvement (arterial or venous thromboses, aneurysms) 1
- Recurrent genital aphthous ulcers 2
- Ocular involvement (hypopyon-iritis, uveitis) 2
- CNS involvement (meningo encephalitis) Nerve paralysis 1
- Positive pathergy test 1

Adamantiades-Behçet disease: 4 or more points

• Etiopathogenesis of

BD

1. Genetic — HLA5
n 51
v B27

2. Immunologic: Type II
reacts (Immune complex)

3. Inf.: HSV, HCV, strep


Age: 20-35

Sex: M > F.

48

سبب
الوفاة

- Lines of TTT : According to The European League Against Rheumatism recommendations from 2008.



Therapeutic ladder for complex aphthosis Behçet's disease

Complex aphthosis / mucocutaneous disease

- Topical @ intralesional corticosteroids
- Colchicine — S-E — Anti-Beta — Anesth
- Dapsone
- Combination of the above

Severe mucocutaneous disease (Eye)

- Thalidomide
- Low-dose methotrexate (7.5-20 mg/wk)
- Prednisone
- Interferon alpha

Severe ocular & systemic disease

- Prednisone — A
- Azathioprine (1-2 mg/kg/day) — B
- Cyclophosphamide — C
- Chlorambucil — S
- Cyclosporine (10 mg/day)

1. Recurrent oral ulcers:

Recurrent ulcers → recur ≥ 3 times / y (Either reported by patient or reliably Physician).

usually: Painful.

Types.

قرع صغير
مكتلة صالحة
تماماً لقرع أصغر
أحادية.

2

6

4

Minor →	1-5, small (<10mm) moderately painful resolve in "4-14 d's" without scar (scarring only in 10%)
Major →	1-10 large (10-30mm) very painful persist upto 6ws → Scar (60%) High incid. of Antimucosal Abs.
Herpetiform →	Recurrent crops of as many as 10-100 small (2-3mm) painful ulcers. Heal: upto 4ws. Low incid. of Antimucosal Abs.

2. Recurrent Genital ulcers:

♂: Scrotal > penile
♀: vulva, vagina, ex.

3. Ocular

Rehnitis & Post Uveitis (التهقيل)
A leading cause of morbidity & blindness.

4. other skin lesions →

التهقيل

5. Pathergy test

(التهقيل)

Def. Hypersensitivity test (ar) demonstrate
↑ Neutrophil chemotaxis at site of
Trauma. (..... Koebner phenomenon) (فلس)

Method:

Needle Prick or ID injection of
oil of Saline or histamine 1-2 ds
Erythematous papule or sterile pustule (> 2mm)

Results: may be +ve or -ve, if -ve → repeat at
2-5 points before results.

6. Systemic manifestations

CNS → Meningo-encephalitis
Nerve palsy
Thrombosis
Vascular (large) → Aneurysm
Hemorrhage

GIT
Joint.

Syndrome (BADAS) (66)

(Bowel by pass synd)

QD in IBD

① By-pass operation to create

blind loop as:

. Jejunocolic by-pass surgery

. Gastric by pass

استئصال
الغزوة
PU

② Bile pancreatic diversion

③ IBD

④ Diverticulitis

Bacterial over growth in the

blind loop → release of bacteria

. Ag. (as peptidoglycans) → Immune

Complex formation → deposit in

SKIN & Joint.

↓ (1-6 yrs) بعد الجراحة

Manifests as BADAS: ١-٦ سنة

A. Cut. manifest. (Dermatosis = ND):

① usually: Erythematous macules → papules →
purpuric vesiculopustules (within 48 hrs)

تقرحات حبيبية دموية وتقرحات حبيبية

Commonest sites: Extremities & trunk.

② Other lesions: Erythematous S.C

Nodules at ±:


EN

or Nodular non-suppurative Panniculitis

DD

③ Arthritis

④ Nutritional deficiency



Roux-Y Gastric Bypass operation

EN
on spring
Septal
intra-culic
legs

Nodular
non supp.
Panniculitis

. Scarring (depressed)

. lobular

. at legs, buttocks
& abd.

Neutrophilic Dermatositis (Pustular Vasculitis)

of dorsal Hand

(68)

- Some consider it as a localized variant of Sweet Syndrome.
- CIP Edematous ulcerative or pustular Nodules & plaque at dorsal Hands.
- path. : as Sweet but There may be Lev.
- tt : as Sweet.

Neutrophilic Eccrine Hidradenitis

def. ND ch by inflamm. of Eccrine sweat gland.

CIP : غالباً يحصل بر حصة الليباري
(دفعه Cytarabin) بشره اليد
علاج حالات الـ Leukemia & Lymphoma
بغالباً ينال في الطرف كونه
Neutropenia.

lesion : Erythematous, Edematous, papules,
Acral plaques, Purpura & Pustules located
at : Face → periorbital eyes
Palm
Extremities.

There may be fever.

tt → NSAIDs
Dapsone
Cs.

Extracut ND (MedCape.com → NCERT).

NB: on Behcet dis (BD)

• Histopathology

- Early: Neutrophilic Vascular Reaction
- Late: Lymphocytic Vasculitis
- According to Chaplin HCC (2012) → Variable Vasculitis

• Behcet [له ۳، اخوات ۵۵۵]

1. RAS: Recurrent Aphthous Stomatitis.
2. Complex Aphthosis
3. MAGIC Snd: Mouth & genital ulcers with Inflamed Carriage.

Complex Aphthosis

def 3 \leftarrow recurrent oral ulcers
" genital "
No systemic manifest of BD

• Controversy is it early BD or Form Frustr.

على حساب الـ (New Criteria of BD)
لا يوجد حاجة أسنفاً
[هـ تعتبر BD]

• RAS = ReCurrent Aphthous stomatitis

- Commonest ulcerative dis. of oral cavity (20% of populatn)
- Predisposing Factors:
 Celiac

III
Diab. Mell.


- Susposing Factors:
- (1) BD
 - (2) Malabsorption — Celiac
 Crabbs
 - (3) Stress (4) Cessate of Smoking
 - (5) Trauma & Certain Foods
 - (6) Inf. — Strep.
 H. pylori
 - (7) Idiopathic

- HT
- ① Topical:
- Tetracycline mouth wash
 - Anaesthetic Cs
- ② Systemic
- Dapsone
 - Colchicine
 - Thalidomide
 - Azathioprine


- Types of ulcers: minor (80%), Major (10%), Herpetiform (10%)

DD of oral ulcer(s) / Erosion(s)

(see Regional Dermatology, Vol. 2)



DD of oral ulcer(s) / Erosion(s)



Complex Aphthosis: ≥ 3 oral ulcers + Genital ulcers but NO systemic Manifest. of BD

Oculomucocut Synd. (DD of BD)

- | | |
|-----------------------|----------------------------|
| [BD ^{Bleph} | [PV |
| [EM | [CP |
| [Sweet | [$\text{\textcircled{S}}$ |
| [Reiter's | [HSV |
| | [LE |
| | [MCTD |

Eosinophilic dermatoses

(75)

(discuss ch by)

3 p.p.v → ① Well's synd

② Granuloma Faciale

③ Hypereosinophilic synd.

Predominant Eosinophilic infiltrate

as evident of Eos. degran. (Peripheral Blood Eosinophilia)

Well's synd (Eosinophilic Cellulitis)

Chr. recurrent Cut. disorder CK < Clinically by: Cellulitis like rash
pathologically by: Flame figures.

Etiopath: (1) Arthropod bites

(2) Infect. / Infest.

Viruses
Tinea

Toxocara canis ✓

(3) Myeloprolif.

Epidemiology: Adults, without predilect.

Clin: itchy or burning, indurated Erythematous Nodules & plaques

(cellulitis like) $\xrightarrow{4-8 \text{ w.}}$ Faint-pink, brown or slate gray pigm.

on limbs → recurrente.

There may be < FAHIM, Eosinophilia.

Clinically Varieties: papules, vesiculobullous & Annular.

(path) Deep dermal (± SC or facial) Eosinophilic infiltr.

+ Flame figures [Collagen coated by Eosinophilic granular proteins].

(Lab) Blod $\xrightarrow{\text{Eos.}} \text{Eos. catenaric pln. (ECP)}$
 $\xrightarrow{\text{TILS}}$

Toxocara canis: stool
- IgE
antibodies.

DD

(Clinically) → see pseudocellulitis & cellulitis.

(path) → causes of Flame figure: Arthropod bite, scabies, Eczema, Drug Erupt. & Mastocytoma, Sweet.

dramatic Response ↑

Cs

10-80 mg id tapered over 4m.

desib 44

Others

Topical Cs, Dapsone, Minocycline, Griseofulvin & Antihistamines.

Granuloma Faciale (GF)

(76)

(± self limiting)

(Def) Chr. Ig, Idiopathic skin disorder CL BX

Single or Multiple red-brown cut. Nodules on face.

Etiology ??

Epidemiology Middle age ♂ > ♀

Clin: Single, Asympt., smooth red-brown or violaceous plaque on Face ± prominent follicular opening.

Varies $\begin{cases} \text{Multiple lesions.} \\ \text{Papular lesions.} \\ \text{Extracutaneous GF.} \end{cases}$

Nasal involvement (Eosinophilic angiocentric Fibrosis)

Course $\begin{cases} \text{No Associated systemic} \\ \text{Manifest.} \\ \text{± resolve spont.} \end{cases}$

Path.

diffuse mixed dermal infl. $\begin{cases} E. \\ N. \\ L. \end{cases}$

LCV (±)

Grenz Zone.

DIF

+ve deposition at Vs. wall $\begin{cases} IgG \\ IgA \\ IgM \end{cases}$ & C3.

DD ① 5L

② Sarcoidosis

③ Granulomatous vasculitis

④ EED - (difficult to diff. from Extracutaneous GF; by $\begin{cases} \text{over joints} \\ \text{New Eos.} \\ \text{LCV} \\ \text{No Grenz} \\ \text{Eosid change} \end{cases}$)

TH (often resistant)

1st line: IL (CJ)

2nd line: Dapsone

Clazurimine

Tetracyclines

PUVA

Hyper Eosinophilic Synd (HES)

(77)

Diagnostic Criteria :

- [1]. peripheral Blood Eosinophilia $> 1500 / \text{mm}^3$
For $> 6 \text{ ms}$ (or $< 6 \text{ ms}$ but \pm evidence of organ involvement).
- [2]. Absence of other cause of Eosinophilia e.g. (allergy).
- [3]. Evidence of organ involvement (Thus excluding By Eosinophilia)

Types

1. Myeloproliferative.
2. Lymphoproliferative.

Mucocutaneous lesions

(30% of cases)

- . pruritic Erythematous papules or Nodules.
- . Urticaria & Angioedema
- . Mucosal Failure

Cause of death CHF.

(H):

- . Cs
- . Imatinib